On the evening of July 21, 2021, the awarding ceremony of "2020 top 100 series list of China's pharmaceutical industry" was grandly held in Kunming. Under the leadership of chairman Mr. Zhao Shouming, wanbond pharmaceutical Holding Group Co., Ltd. was successfully selected into the sub list of "2020 top 100 series list of China's pharmaceutical industry" with solid R & D and production strength and steady market promotion ability "Top 100 ranking list of Chinese traditional medicine enterprises in 2020" and won the title of "top 100 enterprise" in "top 100 ranking list of Chinese traditional medicine enterprises in 2020".

It is reported that this selection focuses on the innovation driving force and professional promotion force of pharmaceutical industry enterprises. The innovation driving force is mainly evaluated from the R & D comprehensive index of enterprise R & D investment, and the professional promotion force is rigidly defined according to the terminal quantitative data determined by the final selection needs of clinicians and patients.

Wanbond pharmaceutical Holding Group Co., Ltd. (Stock Code: 002082) is a listed company subordinate to wanbond group, one of the top 5 manufacturing enterprises in China. Its main business is a large health industry focusing on pharmaceutical manufacturing and medical devices.
Its pharmaceutical manufacturing takes wanbond Pharmaceutical Group Co., Ltd. as the core, and has six subsidiaries, including Zhejiang wanbond pharmaceutical raw materials Co., Ltd., Zhejiang Pharmaceutical Sales Co., Ltd. of wanbond Pharmaceutical Group, Hangzhou Pharmaceutical Technology Co., Ltd. of wanbond Pharmaceutical Group, and Jiangsu beskang Pharmaceutical Co., Ltd.

Wanbond Pharmaceutical Group Co., Ltd., founded in 1970 and headquartered in Wenling City, Zhejiang Province, is a high-tech enterprise specializing in the R & D, production and sales of modern traditional Chinese medicine, chemical APIs and preparations.
Since its establishment, wanbond Pharmaceutical Group Co., Ltd. has always adhered to science and technology as the guide, has a perfect R & D system and a R & D team with high professional and technical level and strong independent innovation ability, and has established "China Pharmaceutical University wanbond drug joint R & D center" and "Zhejiang University wanbond traditional Chinese medicine modernization joint research center" "Provincial high-tech enterprise research and Development Center for cardiovascular and cerebrovascular drugs", "academician expert workstation", "the first collaborative innovation alliance of medical research enterprises of pharmaceutical products in China - ginkgo leaf dropping pill collaborative innovation alliance of medical research enterprises" are "key high-tech enterprises of the national Torch Plan" and participate in the drafting of a number of national pharmacopoeia standards.
In 2021, wanbond pharmaceutical Holding Group Co., Ltd. will further give play to its R & D and production advantages, explore and innovate, promote the high-quality development of traditional Chinese medicine industry, accelerate the modernization, industrialization and internationalization of traditional Chinese medicine, and contribute to the development of traditional Chinese medicine.